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Summary:
Busulfan pharmacokinetic parameters are useful in
predicting the outcome of allogeneic bone marrow
transplantation (BMT). Standard pharmacokinetic
measurements require multiple blood samples. Various
limited sampling models (LSM) have been proposed for
reducing the sample number required for these
measurements, essentially for patients with malignant
disorders undergoing BMT. This study was undertaken
to evaluate the existing LSM for busulfan pharmacoki-
netics to find out the most suitable method for patients
with thalassaemia major undergoing BMT. Busulfan
levels in plasma samples were analysed by HPLC. The
AUC calculated by non-compartmental analysis using
the program ‘TOPFIT’ was compared with previously
published LSMs. Our seven sample pharmacokinetic
data for AUC calculation was compared with the pub-
lished LSMs. The three sample models suggested by
Chattergoon et al and Schuler et al showed significant
agreement with AUC TOPFIT (R2 = 0.98 and 0.94,
respectively) in our clinical context. Other models
resulted in significant over or under representation of
observed values (Vassal’s model R2 = 0.61; Chat-
tergoon’s two sample model R2 = 0.84; four sample
model R2 = 0.83; Schuler’s two sample model R2 = 0.79).
By these data the three sample LSM proposed by Chat-
tergoon et al and Schuler et al are suitable for calcu-
lation of the AUC in patients with thalassaemia major
undergoing BMT conditioned with oral busulfan. Bone
Marrow Transplantation (2001) 28, 821–825.
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mia; bone marrow transplantation
Busulfan, a bifunctional alkylating agent of the methyl sul-
fonate group, in combination with cyclophosphamide is
widely employed in conditioning regimens for bone mar-
row transplantation (BMT),1–3 A large number of studies
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has shown that several factors including age of the
patient,4–6 underlying disease,7,8 chronopharmacology,9,10
food11 and concomitant administration of other drugs12
affect the pharmacokinetics of oral busulfan. It has also
been demonstrated that both in adult and pediatric patients,
dose adjustment according to pharmacokinetic parameters
could improve the outcome of allogeneic BMT by reducing
regimen-related toxicities and relapse of disease.13,14 Most
patients with thalassaemia major undergoing BMT have
abnormal liver functions due to iron overload and hepatitis
virus infections.15 A high incidence of hepatic toxicities
related to conditioning therapy has been reported.16 We
have also shown that there is a correlation between busulfan
pharmacokinetics and rejection in these patients.17 Evalu-
ation of busulfan pharmacokinetics therefore acquires
particular significance in these patients.
The conventional seven to 12 sample (per dose) model
is accurate for analysis of busulfan kinetics but requires
frequent blood sampling, which is inconvenient for the
patient, nursing and laboratory staff, and increases the cost
of evaluation. Various studies have proposed limited sam-
pling models (LSM) for determination of AUC based on
two to three samples per dose of busulfan. These LSM
approaches provided data comparable to those of conven-
tional sampling procedures but without the disadvantages
of the latter. However, such correlations have essentially
been assessed in patients with malignant disorders undergo-
ing BMT. So far, LSMs have not been evaluated in children
with non-malignant inherited disorders. The purpose of this
study was to explore whether a LSM was applicable to
patients with thalassaemia major undergoing BMT. To this
end, we have compared the busulfan AUC (calculated by
TOPFIT) obtained from conventional multisampling pro-
cedure to that obtained by LSM procedures in order
to establish the most suitable method for patients with
thalassaemia major.
Patients and methods
Patients
Patients with beta thalassaemia major undergoing BMT
were assigned to one of the two conditioning regimens as
LSM for busulfan pharmacokinetics in thalassaemia
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previously described:18 regimen A: busulfan 16 mg/
kg + ALG + cyclophosphamide 200 mg/kg and regimen B:
busulfan 600 mg/m2 + cyclophosphamide 200 mg/kg.
Blood samples from children with thalassaemia were col-
lected in heparinized tubes before each dose and after 0.5,
1, 1.5, 2, 4 and 6 h after doses 1, 2 and 13. Informed con-
sent was obtained from the patients’ parents and ethical
approval was obtained from the Institutional Review Board.
Pharmacokinetic analysis
Busulfan in plasma samples was analysed by HPLC as pre-
viously described.19 AUC was calculated by non-compart-
mental analysis using the computerized program TOPFIT
(version 2.0).20
Limited sampling models
The AUC in the published LSM are calculated by using a
combination of the trapezoidal rule, which is used to calcu-
late AUC from time 0 to a particular dosing interval (eg
0–6 h) and the logarithmic rule, which derives the extrapo-
lated AUC up to infinity using the formula Cx/Ke, where
Cx = plasma concentration at time x after the dose and Ke
is the elimination rate constant. These formulae were
arrived at by stepwise multiple linear regression with the
AUC as dependent and the individual concentrations as
independent variables. Busulfan AUC calculated by TOP-
FIT was compared with AUCs calculated using the follow-
ing LSMs:
(1) Chattergoon et al:21
two sample AUC = 30C1h + 300C1h/(Ln C1h −
LnC6h)
three sample AUC = 45C1h + 15C1.5h +
270C1.5h/(Ln C1.5h − Ln C6h)
four sample AUC = 45C1h + 30C1.5h + 15C2h +
270C2h/(Ln C2h − Ln C6h)
(2) Vassal et al:22 AUC = 122 + 0.97C0.5h + 13.94C6h
(3) Schuler et al:11
two sample AUC = 782 + 1.42C1h + 3.74C4h
three sample AUC = 289 + 1.16C1h + 1.06C2h +
3.16C4h
where C0.5h, C1h, C1.5h, C2h, C4h and C6h represents the bus-
ulfan plasma concentrations after 0.5, 1, 1.5, 2, 4 and 6 h,
respectively, of busulfan dose; Ln represents the natural
logarithm. Chattergoon’s and Vassal’s models were pro-
posed for children and estimate AUC 0–inf whereas Schu-
ler’s model was proposed for adults and estimates AUC
0–6 h.
Statistical analysis
Linear regression analysis was applied to compare the
AUCs calculated by TOPFIT vs AUC calculated by various
LSMs, using SPSS version 7.5 for Windows.
Results and discussion
The estimated AUC values derived from different LSM
protocols were compared with AUC values obtained from
conventional measurement of all samples using TOPFIT20
(Table 1). When analyzed by linear regression analysis, a
significant agreement (R2 = 0.79–0.98) was found between
all these models except with the model proposed by Vassal
et al22 (R2 = 0.61, Table 1). The mean difference in the cal-
culated AUC for each of these models from the observed
values was less than 5% for all except the two sample
model of Chattergoon et al21 and the model proposed by
Vassal et al22 where it was lower by 5.29% and 6.38%,
respectively. Figure 1 describes the linear regression of
AUCs calculated by all the proposed LSMs vs TOPFIT.
Figure 2 shows the ratio plots of AUCs estimated by these
models and those determined by TOPFIT.
The best correlation was found between AUC TOPFIT
and the three sample LSM of Chattergoon et al21
(R2 = 0.98). Although all other models except the one pro-
posed by Vassal et al22 correlated significantly, the mean
difference was much lower with this model (2.35%, range
1.6–5.5%). AUC (0–6 h) calculated by Schuler’s11 three
sample LSM also showed a good agreement (R2 = 0.94)
with AUC (0–6 h) TOPFIT, with a mean difference of
1.38% (range 0.6–2.5%), although this model was proposed
for adults. However, Hassan et al23 have reported that this
model of Schuler et al’s11 resulted in a mean underestim-
ation of 25% (range 2–50%) in the calculation of AUC in
children and that the differences were more pronounced at
higher AUCs. It was their conclusion that Schuler’s model
was proposed for AUC calculation in adults and it therefore
cannot be used to estimate AUC in children. A similar dis-
crepancy was observed by Chattergoon et al21 when com-
pared with Schuler’s LSM. Schuler’s AUC calculations
were based on AUC 0–6 h at first dose, whereas Chat-
tergoon and Hassan calculated AUC 0–inf. It is remarkable
that our data from children with thalassaemia major corre-
lated well with Schuler’s three sample LSM in adults. The
reason for this is not clear but suggests that the cause of
discordance noted by Hassan and Chattergoon may not be
the age difference of the subjects studied. Schuler’s two
sample model showed a less significant agreement with
AUC (0–6 h) TOPFIT than the three sample model
(R2 = 0.79).
Vassal’s22 LSM was proposed for children in the age
range of 1.92 to 13.83 years. When we applied it for calcu-
lating AUC for our patient group, we noted significant
differences when compared to the AUC obtained by con-
ventional multisample procedure using TOPFIT, with a
mean difference of 6.4% (range 1–26%). This discrepancy
may be attributed to variation in Tmax observed in the
present study (0.5–6 h). The median Tmax in the present
study was 1.5–2 h and Vassal’s22 model does not use 1.5h
or 2h value for AUC calculation. This might explain the
observed correlation with other LSMs (all of which include
a 1.5 h or 2 h value) with TOPFIT and not with Vassal’s22
model. Previously it was reported21,23 that Vassal’s22 LSM
gave closer results to the determined values, but with a
higher degree of variation and a tendency for overestim-
ation at higher AUCs, which was most probably due to
LSM for busulfan pharmacokinetics in thalassaemia
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Table 1 Comparison of AUC TOPFIT with published LSM
AUC (0–inf) Chattergoon’s LSM Vassal’s LSM Schuler’s LSM
TOPFIT
2 sample 3 sample 4 sample 2 sample 3 sample
Mean AUC ± s.d. 3526 ± 855 3054 ± 787 3411 ± 710 3207 ± 963 3577 ± 1212 2898 ± 779 3249 ± 765
CV (%) — 10 4 9 13 12 3.3
R2 value — 0.87 0.97 0.83 0.61 0.89 0.94
Mean % diff — 5.29 2.35 3.19 6.38 3.69 1.38
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Figure 1 Comparison of AUC TOPFIT with different LSMs. (a–f) Linear regression curves for AUC TOPFIT vs AUCs determined by different LSMs:
(a, b and c) correlation between AUC TOPFIT and the determined AUCs calculated using (a) two, (b) three, and (c) four sample LSMs of Chattergoon
et al;21 (d) correlation between AUC TOPFIT and the determined AUCs calculated using Vassal’s LSM;22 (e and f) correlation between AUC TOPFIT
and the determined AUCs calculated using two and three sample LSM of Schuler et al.11
wider variation in concentration at 0.5h after adminis-
tration. We could not make a comparison with Hassan’s23
model because there was no 3 h sample in the present study.
Of all these models, Chattergoon’s21 three sample model
and Schuler’s11 three sample model showed the maximum
Bone Marrow Transplantation
agreement with our AUC determined by TOPFIT. Simi-
larly, Chattergoon et al21 showed the highest agreement
between their three sample model and the AUC determined
by the KINFIT program.24 Although other authors have
compared the published LSMs for AUC calculations with
LSM for busulfan pharmacokinetics in thalassaemia
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Figure 2 Ratio plots of AUC estimated by different LSM vs AUC estimated by TOPFIT. (a–f) Ratio plots made by plotting AUC TOPFIT (ng*h/ml)
vs the ratio of AUC estimated by TOPFIT/AUC determined by different LSMs: (a, b and c) Relationship between AUC determined by TOPFIT and
estimated/determined AUCs for (a) two sample, (b) three sample and (c) four sample LSM of Chattergoon et al;21 (d and e) Relationship between AUC
determined by TOPFIT and estimated/determined AUCs for (d) two sample and (e) three sample LSM of Schuler et al;11 (f) Relationship between AUC
determined by TOPFIT and estimated/determined AUCs for LSM of Vassal et al.22
their models,21,23 none of the authors reported significant
correlation between the models. The correlation of determ-
ined AUC observed in the present study with other models
could be due to the use of the non-compartmental model
for AUC calculation in this study, as opposed to the one
compartment models used by Hassan22 and Chattergoon.21
In conclusion, we have identified Chattergoon’s21 (using
1 h, 1.5 h and 6 h samples) and Schuler’s (using 1, 2 and
4 h samples) three sample models to be the most suitable
for AUC calculation in children with thalassaemia major
for busulfan dose adjustment. These data can now be used
to apply LSM for assessment of busulfan pharmacokinetics
in patients with thalassaemia major undergoing BMT and
thus contribute to cost reduction, and convenience in
sample analysis and above all patient’s comfort.
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